iShares US Pharmaceuticals ETF (NYSEARCA:IHE) Stock Holdings Lifted by First Republic Investment Management Inc.

First Republic Investment Management Inc. lifted its position in iShares US Pharmaceuticals ETF (NYSEARCA:IHEGet Rating) by 76.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,311 shares of the company’s stock after acquiring an additional 1,874 shares during the quarter. First Republic Investment Management Inc.’s holdings in iShares US Pharmaceuticals ETF were worth $861,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Raymond James Financial Services Advisors Inc. boosted its position in iShares US Pharmaceuticals ETF by 4.2% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 3,618 shares of the company’s stock worth $723,000 after acquiring an additional 147 shares during the period. Steward Partners Investment Advisory LLC lifted its position in shares of iShares US Pharmaceuticals ETF by 0.8% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 16,728 shares of the company’s stock worth $3,339,000 after purchasing an additional 134 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of iShares US Pharmaceuticals ETF by 29.1% during the fourth quarter. Bank of America Corp DE now owns 33,748 shares of the company’s stock worth $6,737,000 after purchasing an additional 7,597 shares during the period. Raymond James & Associates grew its position in iShares US Pharmaceuticals ETF by 4.5% during the fourth quarter. Raymond James & Associates now owns 31,446 shares of the company’s stock valued at $6,278,000 after purchasing an additional 1,354 shares in the last quarter. Finally, Envestnet Asset Management Inc. increased its stake in iShares US Pharmaceuticals ETF by 14.1% in the 4th quarter. Envestnet Asset Management Inc. now owns 10,218 shares of the company’s stock valued at $2,040,000 after buying an additional 1,259 shares during the period.

Shares of NYSEARCA:IHE opened at $186.61 on Friday. The firm has a fifty day moving average of $191.79 and a two-hundred day moving average of $191.31. iShares US Pharmaceuticals ETF has a 12-month low of $176.96 and a 12-month high of $202.77.

iShares US Pharmaceuticals ETF Company Profile (Get Rating)

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.

Recommended Stories

Want to see what other hedge funds are holding IHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares US Pharmaceuticals ETF (NYSEARCA:IHEGet Rating).

Institutional Ownership by Quarter for iShares US Pharmaceuticals ETF (NYSEARCA:IHE)

Receive News & Ratings for iShares US Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares US Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.